Published in:
01-02-2011 | Research Article
DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy
Authors:
Hyunki Kim, Karri D. Folks, Lingling Guo, Cecil R. Stockard, Naomi S. Fineberg, William E. Grizzle, James F. George, Donald J. Buchsbaum, Desiree E. Morgan, Kurt R. Zinn
Published in:
Molecular Imaging and Biology
|
Issue 1/2011
Login to get access
Abstract
Purpose
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts.
Procedures
Groups 1–4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining.
Results
DCE-MRI measured a significant K
trans change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K
trans changes followed quadratic polynomial curves.
Conclusion
DCE-MRI detected significantly lower K
trans levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.